نتائج البحث - "Mennitto A."

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/27462141; info:eu-repo/semantics/altIdentifier/wos/WOS:000379332100001; volume:10; firstpage:2167; lastpage:2172; numberofpages:6; journal:DRUG DESIGN, DEVELOPMENT AND THERAPY; http://hdl.handle.net/2434/442270Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84978970987

الإتاحة: https://doi.org/10.2147/DDDT.S104225Test
http://hdl.handle.net/2434/442270Test

View record in BASE

4

Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma

المؤلفون: Alessia Mennitto, Pierangela Sepe, Francesca Corti, Giuseppe Procopio

المصدر: ImmunoTargets and Therapy. 9:273-288

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::7f41b2e2e5b98872abc48a1f36bf7e78Test
https://doi.org/10.2147/itt.s240889Test

5

دورية أكاديمية

Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial

المؤلفون: Mennitto, A, Verzoni, E, Cognetti, F, Miceli, R, Milella, M, Mosca, A, Chiuri, V E, Bearz, A, Morelli, F, Ortega, C, Atzori, F, Donini, M, Claps, M, Guadalupi, V, Sepe, P, Cappelletti, V, de Braud, F G, Procopio, G

المساهمون: Mennitto, A, Verzoni, E, Cognetti, F, Miceli, R, Milella, M, Mosca, A, Chiuri, V E, Bearz, A, Morelli, F, Ortega, C, Atzori, F, Donini, M, Claps, M, Guadalupi, V, Sepe, P, Cappelletti, V, de Braud, F G, Procopio, G

مصطلحات موضوعية: Metastatic renal cell carcinoma, adjuvant treatment, relapse-free survival, sorafenib, surgical metastasectomy, targeted therapy, Antineoplastic Agents, Carcinoma, Renal Cell, Disease-Free Survival, Follow-Up Studies, Humans, Kidney Neoplasms, Metastasectomy, Neoplasm Recurrence, Local, Probability

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33472450; info:eu-repo/semantics/altIdentifier/wos/WOS:000613363500001; volume:14; issue:2; firstpage:261; lastpage:268; numberofpages:8; journal:EXPERT REVIEW OF CLINICAL PHARMACOLOGY; http://hdl.handle.net/11562/1063756Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85100181589

الإتاحة: https://doi.org/10.1080/17512433.2021.1879639Test
http://hdl.handle.net/11562/1063756Test

View record in BASE

6

Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial

المؤلفون: Franco Morelli, Francesco Atzori, Melanie Claps, Maddalena Donini, Alessandra Mosca, Vera Cappelletti, Alessandra Bearz, Rosalba Miceli, Elena Verzoni, Cinzia Ortega, Francesco Cognetti, M. Milella, Valentina Guadalupi, Pierangela Sepe, V.E. Chiuri, Alessia Mennitto, F. de Braud, Giuseppe Procopio

مصطلحات موضوعية: Sorafenib, Oncology, medicine.medical_specialty, relapse-free survival, medicine.medical_treatment, Cell, Metastatic renal cell carcinoma, adjuvant treatment, Antineoplastic Agents, urologic and male genital diseases, 030226 pharmacology & pharmacy, Relapse free survival, Disease-Free Survival, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, Internal medicine, surgical metastasectomy, Medicine, Humans, Pharmacology (medical), In patient, General Pharmacology, Toxicology and Pharmaceutics, Carcinoma, Renal Cell, Probability, business.industry, Carcinoma, Metastasectomy, Renal Cell, General Medicine, medicine.disease, targeted therapy, Kidney Neoplasms, medicine.anatomical_structure, Neoplasm Recurrence, Local, 030220 oncology & carcinogenesis, Neoplasm Recurrence, Local, business, medicine.drug, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c32b2f4c30474e2235fb342aa61cd1a5Test
http://hdl.handle.net/11562/1063756Test

7

دورية أكاديمية

Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: Real-world data from an Italian managed access program

المؤلفون: Prisciandaro M., Ratta R., Massari F., Fornarini G., Caponnetto S., Iacovelli R., De Giorgi U., Facchini G., Scagliarini S., Sabbatini R., Caserta C., Peverelli G., Mennitto A., Verzoni E., Procopio G.

المساهمون: Prisciandaro, M., Ratta, R., Massari, F., Fornarini, G., Caponnetto, S., Iacovelli, R., De Giorgi, U., Facchini, G., Scagliarini, S., Sabbatini, R., Caserta, C., Peverelli, G., Mennitto, A., Verzoni, E., Procopio, G.

مصطلحات موضوعية: c-Met, cabozantinib, nonclear cell, renal cell carcinoma, targeted therapy, Administration, Oral, Aged, Anilide, Carcinoma, Renal Cell, Disease-Free Survival, Female, Human, Kidney Neoplasm, Male, Middle Aged, Pyridine, Treatment Outcome

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/30204614; info:eu-repo/semantics/altIdentifier/wos/WOS:000458278300008; volume:42; issue:1; firstpage:42; lastpage:45; numberofpages:4; journal:AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS; http://hdl.handle.net/11573/1341170Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85058886805

الإتاحة: https://doi.org/10.1097/COC.0000000000000478Test
http://hdl.handle.net/11573/1341170Test

View record in BASE